Drugs / adipose-derived multipotent mesenchymal stem cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04785027 | Mar → Jun 2021 | psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT03392311 | Jul → Oct 2019 | poisoning, psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT03265613 | Sep 2017 → Aug 2019 | psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04275024 | Apr → Jun 2020 | poisoning, psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adipose-derived multipotent mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04275024 ↗ |
| Known as | AD-MSCs | “AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg” NCT04275024 ↗ |
| Modality | Cell therapy | “recent breakthroughs involving stem cell therapy, in particular, adipose tissue-derived from mesenchymal stem cells (AD-MSCs), have been promising.” PMID 34988162 ↗ Nov 2021 |
| Route | Intravenous | “Patients received intravenous injections of AD-MSCs (0.5×106 cells/kg) monthly for 12 weeks.” PMID 34988162 ↗ Nov 2021 |